Sp157
PRE- AND POST-TRANSPLANT MANAGEMENT OF PATIENTS WITH PSC AND IBD
Date
May 18, 2024
Presenter
Tracks
Related Products
WEARABLE PERSPIRATION SENSOR FOR CONTINUOUS INFLAMMATION TRACKING IN INFLAMMATORY BOWEL DISEASE
Wearable sensors present an opportunity to monitor inflammation via noninvasive mediums such as perspiration, which can be sampled continuously to track inflammation-related markers in inflammatory bowel disease (IBD)…
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
RISANKIZUMAB EFFECTIVENESS IN USTEKINUMAB-NAIVE AND USTEKINUMAB EXPERIENCED PATIENTS WITH CHROHN'S DISEASE: REAL WORLD DATA FROM A LARGE TERTIARY CENTER
<div style="direction: ltr;">BACKGROUND AND AIMS: Risankizumab and ustekinumab are both IL23 inhibitors approved the treatment of moderate to severe Crohn’s disease (CD)…
